Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Sipuleucel-T is well tolerated in this population, says Graff. Some patients have some itching or a slight fever, but both are both easily managed.

Although it has shown benefit, one of the challenges with sipuleucel-T is that it does not shrink tumors, Graff adds.